Publikationen der Klinik für Strahlentherapie und Onkologie

Hier finden Sie die Publikationen der Klinik für Strahlentherapie und Onkologie der letzten Jahre.

Publikationen 2020

Attenberger U, Rödel C, Ghadimi M, Piso P, Arnold D, Folprecht G, Geissler M, Hegewisch-Becker S, Heinemann V, Kasper S, Modest D, Reinacher-Schick A, Seufferlein T, Stein A, Stintzing S, Hofheinz RD. Prerequisites of magnetic resonance imaging for treatment planning in locally advanced rectal cancer - Interdisciplinary recommendations. Z Gastroenterol 2020;58:577-582. (Pubmed-Link).

Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Rödel C, Fokas E. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial. JAMA Oncol  2020; epub ahead of print (Pubmed-Link).

Fietkau R, Hecht M, Hofner B, Lubgan D, Iro H, Gefeller O, Rödel C, Hautmann MG, Kölbl O, Salay A, Rübe C, Melchior P, Breinl P, Krings W, Gripp S, Wollenberg B, Keerl R, Schreck U, Siekmeyer B, Grabenbauer GG, Balermpas P, PacCis-Study Group.. Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial, Radiother Oncol 2020;144:209-217. (Pubmed-Link).

Fokas E, Glynne-Jones R, Appelt A, Beets-Tan R, Beets G, Haustermans K, Marijnen C, Minsky BD, Ludmir E, Quirke P, Sebag-Montefiore D, Garcia-Aguilar J, Gambacorta MA, Valentini V, Buyse M, Rödel C. Outcome measures in multimodal rectal cancer trials. Lancet Oncol 2020 ;21:e252-e264. (Pubmed Link).

Freund I, Hehlgans S, Martin D, Ensminger M, Fokas E, Claus Rödel C, Löbrich M, Rödel F. Fractionation-dependent radiosensitization by molecular targeting of Nek1. Cells 2020;9:E1235. (Pubmed-Link).

Gaipl U, Multhoff G, Pockley G, Rödel F.  Editorial: Radioimmunotherapy—Translational Opportunities and Challenges. Front Oncol 2020;10:190. (Pubmed-Link).

Guberina M, Sak A, Pöttgen C, Tinhofer-Keilholz I, Budach V, Balermpas P, Von der Grün J, Rödel CM, Gikka E, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs S, Mönnich D, Zips D, De-Colle C, Welz S, Linge A, Lohaus F, Baretton G, Gauler T, Baumann M, Krause M, Schuler M, Bankfalvi A, Höing B, Lang S, Stuschke. MERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. Pharmacogenomics J. 2020; epub ahead of print. (Pubmed-Link)

Ludmir EB, Fuller CD, Moningi S, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Verma V, Smith BD, Smith GL, VanderWalde NA, Holliday EB, Guadagnolo BA, Stinchcombe TE, Jagsi R, Gomez DR, Minsky BD, Rödel C, Fokas E. Sex-Based Disparities Among Cancer Clinical Trial Participants. J Natl Cancer Inst 2020;112:211-213. (Pubmed-Link).

Martin D, Rödel F, von der Grün J, Rödel C, Fokas E. Acute organ toxicity correlates with better clinical outcome after chemoradiotherapy in patients with anal carcinoma. Radiother Oncol 2020;epub ahead of print (Pubmed-Link).

Martin D, von der Grün J, Rödel C, Fokas E. Management of anal cancer patients - a pattern of care analysis in German-speaking countries. Radiat Oncol 2020;15:122. (Pubmed-Link).

Martin D, Rödel C, Fokas E. Influence of treatment compliance on the success of chemoradiotherapy for anal carcinoma. Strahlenther Onkol 2020; epub ahead of print. (Pubmed-Link)

Martin D, Balermpas P, Gollrad J, Weiß C, Valentini C, Stuschke M, Schäfer H, Henckenberens C, Debus J, Krug D, Kuhnt T, Brunner T, Bostel T, Engenhart-Cabillic R, Nestle U, Combs S, Belka C, Hautmann M, Hildebrandt G, Gani C, Polat B, Rödel C, Fokas E. RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. Clin Transl Radiat Oncol 2020;23:43-49. (Pubmed-Link).

Michaelis M, Voges Y, Rothweiler F, Weipert F, von Deimling A, Westermann F, Rödel F, Wassa M, Cinatl J. Testing of the survivin suppressant YM155 in a large panel of drug-resistant neuroblastoma cell lines. Cancers 2020;12:E577. (Pubmed-Link).

Michaelis M, Wass M, Reddin I, VogesY, RothweilerF, Hehlgans S, MernbergerM, NistA, Stiewe T, Rödel F, Cinatl J. Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of specific biomarkers for the acquired resistance setting, Cancers 2020;12:E1080. (Pubmed-Link).

Marijnen CAM, Peters FP, Rödel C, Bujko K, Haustermans K, Fokas E, Glynne-Jones R, Valentini V, Spindler KG, Guren MG, Maignon P, Calvo FA, Pares O, Glimelius B, Sebag-Montefiore D. International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. Radiother Oncol 2020 epub ahead of print (Pubmed-Link)

Rödel F, Arenas M, Ott O, Fournier C, Georgakilas AG, Tapio S, Trott KR, Gaipl US. Low-dose radiation therapy for COVID-19 pneumopathy: What are the evidences? Strahlenther Onkol 2020;epub ehaed of print (Pubmed-Link).

Schmid SC, Koll FJ, Rödel C, Maisch P, Sauter A, Beckert F, Seitz A, Kübler H, Flentje M, Chun F, Combs SE, Schiller K, Gschwend JE, Retz M. Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT). BMC Cancer 2020;20:8. (Pubmed-Link).

Schmidt S, Linge A, Großer M, Lohaus F, Gudziol V, Nowak A, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Baumann M, Krause M, Löck S; DKTK-ROG. Comparison of GeneChip, nCounter and real-time polymerase chain reaction based gene expressions predicting loco-regional tumour control after primary and postoperative radiochemotherapy in head and neck squamous cell carcinoma. J Mol Diagn 2020, epub ahead of print (Pubmed-Link).

Schmitt D, Blanck O, Gauer T, Fix MK, Brunner TB, Fleckenstein J, Loutfi-Krauss B, Manser P, Werner R, Wilhelm ML, Baus WW, Moustakis C. Technological quality requirements for stereotactic radiotherapy : Expert review group consensus from the DGMP Working Group for Physics and Technology in Stereotactic Radiotherapy.  Strahlenther Onkol 2020, epub ahead of print. (Pubmed-Link)

Schulz M, Michels B, Niesel K, Stein S, Farin H, Rödel F, Sevenich L. Cellular and molecular changes of brain metastases-associated myeloid cells during disease progression and therapeutic response iScience 2020;23:101178. (Pubmed-Link).

Strouthos I, Tselis N, Ferentinos K, Karagiannis E, Milickovic N, Chatzikonstantinou G, Feder O, Zamboglou N. Intraluminal high-dose-rate brachytherapy - an alternative organ-preserving approach for primary male urothelial carcinoma with panurethral involvement. Pract Radiat Oncol 2020;10:e53-e56 (Pubmed-Link).

Valentini V, Marijnen C, Beets G, Bujko K, De Bari B, Cervantes A, Chiloiro G, Coco C, Gambacorta MA, Glynne-Jones R, Haustermans K, Meldolesi E, Peters F, Rödel C, Rutten H, van de Velde C, Aristei C. The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper.Radiother Oncol 2020;142:6-16. (Pubmed-Link).

von der Grün J, Balermpas P. Radiotherapie mit Cetuximab oder Cisplatin beim Plattenepithelkarzinom der Kopf-Hals-Region – was ist zu bevorzugen? Strahlenther Onkol  2020;196:197-199. (Pubmed-Link).

Voss M, Wagner M, von Mettenheim N, Harter PN, Wenger KJ, Franz K, Bojunga J, Vetter M, Gerlach R, Glatzel M, Paulsen F, Hattingen E, Baehr O, Ronellenfitsch MW, Fokas E, Imhoff D, Steinbach JP, Rödel C, Rieger J. ERGO2: A prospective randomized trial of calorie restricted ketogenic diet and fasting in addition to re-irradiation for malignant glioma. Int J Radiat Oncol Biol Phys 2020; epub ahead of print. (Pubmed-Link).

Wenzel M, Humke C, Wicker S, Mani J, Engl T, Hintereder G, Vogl TJ, Wild P, Köllermann J, Rödel C, Asgharie S, Theissen L, Welte M, Kluth LA, Mandel P, Chun FKH, Preisser F, Becker A. Movember health care initiative 2019: prostate cancer screening at the University Hospital Frankfurt. Urologe A 2020; epub ahead of print. (Pubmed-Link).

Publikationen 2019

Diefenhardt M, Hofheinz RD, Martin D, Beissbarth T, Arnold D, Hartmann A, von der Grün J, Grützmann R, Liersch T, Ströbel P, Grabenbauer GG,  Rieger M, Fietkau R, Graeven U, Weitz J, Folprecht G, Ghadimi M, Rödel F, Rödel C, Fokas E. Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. Int J Cancer 2019;145:2282-2291. (Pubmed-Link).

Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Rödel C, Fokas E. Association of sex with toxic effects, treatment adherence, and oncologic outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 randomized clinical trials of rectal cancer. JAMA Oncol 2019;6:294-6. (Pubmed-Link).

Chae W, Schulz M, Niesel K, Klemm F, Joyce J, Prümmer M, Brill B, Bergs J, Rödel F, Pilatus U, Sevenich L. Evaluating therapeutic response of whole brain radiotherapy in a mouse model for breast-to-brain metastasis using magnetic resonance imaging and spectroscopy. Front Oncol 2019;9:1324 (Pubmed-Link).

Chatzikonstantinou G, Ulrich P, Archavlis E, Zamboglou N, Strouthos I, Zoga E, Baltas D, Tselis N. Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme. J Contemp Brachytherapy 2019;11:215-220 (Pubmed-Link).

Chatzikonstantinou G, Zamboglou N, Baltas D, Ferentinos K, Bon D, Tselis N. Image-guided interstitial high-dose-rate brachytherapy for dose escalation in the radiotherapy treatment of locally advanced lung cancer: A single-institute experience. Brachytherapy 201918:829-834. (Pubmed-Link).

Eder T, Hess AK, Konschak R, Stromberger C, Jöhrens K, Fleischer V, Hummel M, Balermpas P, von der Grün J, Linge A, Lohaus F, Krause M, Baumann M, Stuschke M, Zips D, Grosu A, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs S, Budach V, Tinhofer I. Interference of tumor mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: A multicenter retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Eur J Cancer. 2019;116:67-76. (Pubmed-Link).

Feczkó T, Piiper A, Pleli T, Schmithals C, Denk D, Hehlgans S, Rödel F, Vogl TJ, Wacker MG. Theranostic sorafenib-loaded polymeric nanocarriers manufactured by enhanced gadolinium conjugation techniques.  Pharmaceutics 2019,11:489. (Pubmed-Link).

Fleischmann M, Martin D, Peña-Llopis S, Oppermann J, von der Grün J, Diefenhardt M, Chatzikonstantinou G, Fokas E, Rödel C, Strebhardt K, Becker S, Rödel F, Tselis N. Association of Polo-like kinase 3 and phosphoT273 Caspase 8 with improved survival in patients with cervical squamous cell carcinoma treated with radical chemoradiotherapy and brachytherapy. Front Oncol 2019,9:742. (Pubmed-Link).

Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Schmiegel W,  Jacobasch L, Weitz J, Folprecht G, Schlenka-Lange A, Flentje M, Germer CT, Grützmann R, Schwarzbach M, Paolucci V, Bechstein WO, Friede T, Ghadimi M, Hofheinz RD, Rödel C, German Rectal Cancer Study Group. Randomized Phase II Trial on Chemoradiotherapy plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. J Clin Oncol 2019;37:3212-3222 (Pubmed-Link)

Gani C, Gani N, Zschaeck S, Eberle F, Schaeffeler N, Hehr T, Berger B, Fischer SG, Claßen J, Zipfel S, Rödel C, Teufel M, Zips D. Organ Preservation in Rectal Cancer: The Patients' Perspective .Front Oncol 2019;10;9:318. (Pubmed-Link).

Hausmann J, Kubesch A, von der Grün JM, Goettlich CM, Filmann N, Tal AO, Vermehren J, Friedrich-Rust M, Wächtershäuser A, Bojunga J, Blumenstein I. Prophylactic percutaneous endoscopic gastrostomy in patients with head and neck cancer: influence on nutritional status, utilization rate and complications. Int J Clin Pract 2019;73:e13405. (Pubmed-Link)

Hess AK, Jöhrens K, Zakarneh A, Balermpas P, von der Grün J, Rödel C, Weichert W, Hummel M, Keilholz U, Budach V, Tinhofer I.  Characterization of the Tumor Immune Micromilieu and its Interference with Outcome After Concurrent Chemoradiation in Patients with Oropharyngeal Carcinomas. Oncoimmunology 2019;8:1614858. (Pubmed-Link).

Hess J, Unger K, Maihoefer C, Schüttrumpf L, Wintergerst L, Heider T, Weber P, Marschner S, Braselmann H, Samaga D, Kuger S, Pflugradt U, Baumeister P, Walch A, Woischke C, Kirchner T, Werner M, Werner K, Baumann M, Budach V, Combs SE, Debus J, Grosu AL, Krause M, Linge A, Rödel C, Stuschke M, Zips D, Zitzelsberger HF, Ganswindt U, Henke M, Belka C. A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV-infection. Clin Cancer Res 2019;25:1505-1516. (Pubmed-Link)

Hoey C, Ahmed M, Fotouhi Ghiam A, Vesprini D, Huang X, Commisso K, Commisso A, Ray J, Fokas E, Loblaw DA, He HH, Liu SK. Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy. J Transl Med 2019;17:173. (Pubmed-Link).

Hörner-Rieber JH, Bernhardt D, Blanck O, Duma M, Eich H, Gerum S, Gikka E, Hass P, Henkenberens C, Herold HU, Hildebrandt G, Imhoff D, Kahl H, Janssen S, Jurianz K, Krempien R, Lautenschläger SF, Lohaus F, Mueller AC, Petersen C, Sackerer I, Scafa D, Schrade E,  Uhlmann L, Wittig A, Guckenberger M. Long-term follow-up and patterns of recurrence of oligometastatic NSCLC patients treated with pulmonary SBRT. Clin Lung Cancer 2019;20:e667-e677. (Pubmed-Link).

Kashihara T, Murakami N, Tselis N, Kobayashi K, Tsuchida K, Shima S, Masui K, Yoshida K, Takahashi K, Inaba K, Umezawa R, Igaki H, Ito Y, Kato T, Uno T, Itami J. Hyaluronate gel injection for rectum dose reduction in gynecologic high-dose-rate brachytherapy: initial Japanese experience. J Radiat Res 2019;60:501-508. (Pubmed-Link).

Klement RJ, Abbasi-Senger N, Adebahr S, Alheid H ,Allgaeuer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Eble MJ, Ernst I, Gerum S, Habermehl D, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lewitzki V, Lohaus F, Ostheimer C, Papachristofilou A, Petersen C, Rieber J, Schneider T, Schrade E, Semrau R, Wachter S, Wittig A, Guckenberger M, Andratschk A. The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. BMC Cancer 2019;19:173. (Pubmed-Link)

Lang BM, Balermpas P, Bauer A, Blum A, Brölsch GF, Dirschka T, Follmann M, Frank J, Frerich B, Fritz K, Hauschild A, Heindl LM, Howaldt HP, Ihrler S, Kakkassery V, Klumpp B, Krause-Bergmann A, Löser C, Meissner M, Sachse MM, Schlaak M, Schön MP, Tischendorf L, Tronnier M, Vordermark D, Welzel J, Weichenthal M, Wiegand S, Kaufmann R, Grabbe S. S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 1: Epidemiology, Genetics and Diagnosis . J Dtsch Dermatol Ges 2019;17:94-103. (Pubmed-Link)

Linder B, Wehle A, Bonn F, Hehlgans S, Dikic I, Rödel F. Seifert V, Kögel D. Arsenic Trioxid and (-)-Gossypol synergistically target glioma stem-like cells via Inhibition of Hedgehog and Notch signaling. Cancers 2019:11:350. (Pubmed-Link)

Martin D, Rödel F, Balermpas P, Winkelmann R, Fokas E, Rödel C. C-reactive protein-to-albumin ratio as prognostic marker for anal squamous cell carcinoma treated with chemoradiotherapy. Front Oncol 2019;9:1200 (Pubmed-Link).

Martin D, Rödel C, Fokas E. Chemoradiotherapy for anal cancer: are we as good as we think? Strahlenther Onkol 2019;195:369-373. (Pubmed-Link)

Merten R, Ott O, Haderlein M, Bertz S, Hartmann A, Wullich B, Keck B, Kühn R, Rödel CM, Weiss C, Gall C, Uter W, Fietkau R. Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). Oncologist 2019;24:e1341-e1350. (Pubmed-Link)

Müller-Längle A, Lutz H, Hehlgans S, Rödel F, Rau K, Laube B. NMDA Receptor-mediated signaling pathways enhance radiation resistance, survival and migration in glioblastoma cells - a potential target for adjuvant radiotherapy. Cancers 2019;11:E50. (Pubmed-Link)

Montero A, Sabater S, Rödel F, Gaipl US, Ott OJ, Seegenschmiedt MH, Arenas M. Is it time to redefine the role of low-dose radiotherapy for benign disease? Ann Rheum Dis 2018 Comment, epub ahead of print. (Pubmed-Link).

Murakami N, Shima S, Okuma K, Iijima K, Tselis N, Uematsu M, Takagawa Y, Kashihara T, Masui K, Yoshida K, Takahashi K, Inaba K, Igaki H, Nakayama Y, Itami J. Artificial ascites for organs at risk sparing in intrapelvic brachytherapy: a case report of recurrent uterine cervical carcinoma adjacent to the bowel. BJR Case Rep 2018;5:20180067. (Pubmed-Link)

Murakami N, Shima S, Kashihara T, Tselis N, Kato T, Takagawa Y, Masui K, Yoshida K, Takahashi K, Inaba K, Okuma K, Igaki H, Nakayama Y, Itami J. Hyaluronic gel injection into